Alex Azar’s job hop from drugmaker Eli Lilly tothe Trump administration reflects ever-deepening ties between the pharmaceuticalindustry and the federal government.

A Kaiser Health News analysis shows that hundreds of people haveglided through the “revolving door” that connects the drug industryto Capitol Hill and to the Department of Health and HumanServices.

Azar was confirmed Wednesday as HHS secretary, joiningother former drug industry alumni in top positions.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.